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Summary
AIMS: We investigated contemporary diabetes care, qual-
ity of glycaemic control, and progression of obesity in pa-
tients with diabetes mellitus in different cultural regions
within Switzerland.
METHODS: Overall, 1121 patients treated for type 2 dia-
betes mellitus by 134 general practitioners were enrolled
in this representative, national, cross-sectional survey and
were followed retrospectively from the start of diabetes
treatment. Patients were classified into four cultural re-
gions; the German, French, Italian and Romansh speaking
parts of Switzerland.
RESULTS: During 5.5 ± 5.1 years of diabetes treatment
(retrospective survey), mean HbA1c decreased from 8.28
± 2.01% to 7.03 ± 1.24%, fasting glucose decreased from
9.97 ± 3.86 to 7.52 ± 2.23 mmol/l, and BMI decreased from
30.2 ± 5.5 to 29.8 ± 5.6 kg/m2 (p <0.001 for all paramet-
ers). Insulin therapy was associated with a larger improve-
ment of mean HbA1c (–1.66 ± 2.33% vs. –1.15 ± 1.91%, p
= 0.001) and an increase in BMI (+0.36 ± 2.92 vs. –0.63 ±
2.60 kg/m2, p <0.001). At the time when the cross-sectional
survey was conducted, the mean HbA1c and fasting gluc-
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ose were higher in the Italian part compared to other re-
gions (7.72 ± 1.60% and 9.03 ± 2.49 mmol/l, respectively,
p <0.001), and lower in the German part (6.89 ± 1.02% and
7.25 ± 2.02 mmol/l, respectively, p <0.001). In comparis-
on to other regions, biguanides were more often used in the
French part (86.1% versus 75.7%), insulin secretagogues in
the Italian part (69.9% versus 37.8%), thiazolidinedions in
the Romansh part (34.1% versus 17.8%), and insulin was
more often used in the German part of Switzerland (27.0%
versus 17.1%) (p <0.01 for all parameters).
CONCLUSIONS: Efforts to identify regional-cultural dif-
ferences and attempts to overcome associated potential bar-
riers should be emphasised in any health care system when
aiming for better diabetic patient care.
Key words: glycaemic control; body weight; type 2
diabetes; anti-hyperglycaemic medication; insulin
Introduction
The association between haemoglobin (Hb) A1c levels and
the risk for the development of diabetes-mellitus-related
complications is well established. The European Prospect-
ive Investigation of Cancer and Nutrition (EPIC-Norfolk)
cohort study has shown that an increase of 1% in HbA1c
was associated with a 40% increased risk of coronary heart
disease (16% of cardiovascular disease, and 30% of all-
cause mortality) after adjustment for other risk factors [1].
Therapeutic interventions leading to better control of hy-
perglycaemia and HbA1c levels in patients with type 2
diabetes mellitus have resulted in a significant decline in
micro- and macro-vascular complications [2–5]. Epidemi-
ological and interventional studies have led to the current
treatment recommendations for patients with type 2 dia-
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betes mellitus, targeting HbA1c levels of 7% and below [6,
7]. However, despite these recommendations, a majority of
patients still do not achieve such target HbA1c levels in
general practice [8, 9].
A goal of current research is to identify factors that neg-
atively influence the feasibility and practicability of these
targets in daily clinical practice, in specialised diabetes
clinics and in primary health care, where the vast majority
of patients with type 2 diabetes are taken care of.
Treatment of type 2 diabetes mellitus, including the level
of glycaemic control as well as the type of anti-hyper-
glycaemic medication used, differs significantly between
European countries [8, 10, 11]. Switzerland consists of four
major cultural regions, namely the German, French, Itali-
an speaking parts and the canton of Grisons which repres-
ents the Romansh speaking population, each of them being
linked to their neighbouring European country. However,
treatment recommendations and goals for glycaemic con-
trol and HbA1c levels have been defined nationwide by the
Swiss Society of Endocrinology and Diabetology (SGED)
[12], and Switzerland represents a common economic, so-
cial, educational and health care system. Therefore, we
were particularly interested to compare contemporary dia-
betes care between the four cultural regions of the country.
Patients and methods
Study design
The study design included a cross-sectional as well as a ret-
rospective survey to investigate the quality of glycaemic
control, current diabetes practice and its relationship to car-
diovascular parameters in patients treated for type 2 dia-
betes mellitus in general practice.
General practitioners (GPs) from Switzerland participated
in the study “Quality of Glycaemic Control and Progres-
sion of Obesity in Patients with Type 2 Diabetes in Private
Practice in Switzerland (POIDS)” and enrolled consecutive
patients treated for type 2 diabetes mellitus between
November 3rd and November 7th, 2008.
For data analysis across different language regions,
Switzerland was divided into the four cultural regions by
location of the GPs’ offices: the German, French and Itali-
an speaking parts of Switzerland, and the fourth group from
Figure 1
Distribution of Switzerland into four cultural / language groups
(Green = German speaking, Red = French speaking, Blue = Italian
speaking, Brown = Canton of Grisons / Romansh speaking part).
the canton of Grisons. This represents Switzerland’s fourth
language region (the Romansh speaking part), and most of
this area represents a more rural and mountainous area with
a more difficult accessibility for the health care system (fig.
1).
Based on a power calculation to detect a difference in
HbA1c of 0.5% (estimated standard deviation 1.5%) and
taking into consideration the unequal distribution of the
population among the different cultural regions of Switzer-
land, we formed twelve units (7 German, 3 French, 1 Itali-
an speaking as well as 1 for the Canton of Grisons) with
a similar number of 20 practicing physicians per unit (240
in total). Physicians were randomly selected out of a com-
plete list of all practicing physicians from a centralised na-
tional register and invited to participate in the study. This
revealed a power of the study to detect the above men-
tioned differences in outcome ranging from 60% (smallest
regions) to 95% (largest regions).
Patients treated for type 2 diabetes mellitus (including pa-
tients treated with insulin, oral anti-hyperglycaemic drugs,
and changes in lifestyle or diet only) were included if they
were at least 18 years old and visited the GP within the
screening week period, independently of the reason for
their visit. Patients with type 1 or untreated type 2 dia-
betes mellitus and those unable to sign the informed con-
sent were excluded. Ethics committee approvals were ob-
tained according to local regulations.
Data collection and statistical analysis
Anonymous data on patient actual HbA1c, fasting blood
glucose (FBG), body weight and blood pressure, standard
laboratory parameters including lipid profile and serum
creatinine, as well as current anti-diabetic medication
(cross-sectional survey), were recorded directly by the
treating physician into a standardised case report form
(CRF). If not available in the records, low-density lipopro-
tein (LDL) cholesterol was calculated by the Friedewald
Formula [13]. Similar data from the earlier time point when
diabetes therapy was initiated were also recorded (retro-
spective survey obtained from data written in the patient’s
chart). Data management and data-base entry was per-
formed by an independent data coordinating centre (PFC
Pharma Focus AG, Zurich, Switzerland). Population data
of Switzerland was obtained from the Swiss Federal Stat-
istical Office (Bern).
Continuous variables with a normal distribution were de-
scribed as means with standard deviations (SD) and group
comparisons were performed with the Mann-Whitney Test.
Discrete variables are presented as frequencies and per-
centages and group comparisons were performed using the
Chi-square Test. To compare changes of variables over
time, for continuous variables the Wilcoxon signed-rank
Test and for discrete variables the McNemar Test were
used. The analysis comparing different regions was per-
formed by one-way ANOVA with subsequent application
of a generalised linear model (multiple linear regression)
controlling for the factor of gender and the covariate of
therapy duration. Data were analysed using SPSS Statistics
18.0 software (SPSS Inc.).
For the main comparison of measured parameters between
the different regions, a p-value <0.01 was considered signi-
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ficant (Bonferroni correction applied) and a p-value <0.001
was considered highly significant.
Project funding
The project was funded by sanofi-aventis (suisse) sa,
Meyrin, Switzerland. Data collection, data management
and analysis were independent from the sponsor.
Results
Figure 2
HbA1c measurements at the time of the survey in different cultural
regions of Switzerland. * indicates regions in which HbA1c
measurements differed from the other regions, p <0.001.
Figure 3
Diabetes therapy with different anti-hyperglycaemic drugs at the
time of the survey in different cultural regions of Switzerland. *
indicates regions in which therapy differed from the other regions,
p <0.01.
Overall patient characteristics
In total, 1121 patients were enrolled into the study between
November 3rd and November 7th, 2008. A total of 134
physicians participated in the study, and the enrolment rate
was 8.4 ± 4.3 patients per physician. The mean age of the
patients was 66.1 ± 12.0 years, and 626 (55.8%) were male
(table 1).
Changes of metabolic and cardiovascular parameters
during the retrospective survey in the whole study
population
Fasting glucose, HbA1c, serum creatinine and serum lipids,
as well as body mass index (BMI) and blood pressure at the
time when diabetes therapy was started are shown in table
2, and the same parameters at the time of the current sur-
vey are shown in table 3. As not every measurement was
done in all patients, the number of available measurements
is reported for every parameter as n in the tables. Over-
all, glucose control improved throughout the course of dia-
betes therapy. HbA1c decreased from 8.28 ± 2.01% to 7.03
± 1.24% and fasting glucose decreased from 9.97 ± 3.86
mmol/l to 7.52 ± 2.23 mmol/l (p <0.001 for both paramet-
ers). Serum lipids also ameliorated: Total cholesterol, LDL
cholesterol and triglycerides were lowered, whereas high-
density lipoprotein (HDL) cholesterol levels increased (p
<0.001 for all parameters). Systolic and diastolic blood
pressure were lower at the time of the current survey com-
pared to the start of diabetes therapy (p <0.001 for both
parameters). At the same time, BMI decreased from 30.2 ±
5.5 kg/m2 to 29.8 ± 5.6 kg/m2 (p <0.001), while serum cre-
atinine increased (p <0.001).
Changes in diabetes therapy over time in the whole
study population
Anti-hyperglycaemic medical therapy recorded at the start
of treatment and at the time of the cross-sectional survey
is summarised in tables 2 and 3. During the treatment peri-
od, the proportion of patients treated with at least one anti-
diabetic medication increased from 92.1 to 98.7%, and of
those receiving insulin from 5.7 to 23.6%. Treatment with
more than one anti-hyperglycaemic drug class increased
from 23.7 to 54.3% during the course of therapy with
Figure 4
Changes (%) in BMI, fasting glucose, HbA1c and serum lipids at
the time of the survey compared to the retrospective survey, in
different cultural regions of Switzerland.
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42.1% of the patients being treated with a combination of
2, 11.6% with a combination of 3 and 0.6% with a com-
bination of 4 different anti-hyperglycaemic medications.
Among the patients treated with insulin at the time of the
current survey, 75.2% had at least one additional oral anti-
hyperglycaemic agent.
Region-specific demographic characteristics
Region-specific patient characteristics at the beginning of
anti-hyperglycaemic treatment are shown in table 1. There
was no significant difference in age between the regional
groups at the beginning of diabetes therapy. In the Italian
speaking part of Switzerland, the proportion of male pa-
tients was significantly higher than in the other regions
(69.9% vs. 54.9%, p <0.01). The duration of treatment was
longer in the German speaking (5.9 ± 5.3 y) and shorter in
the French speaking part of Switzerland (4.7 ± 4.5 y) as
well as in the canton of Grisons (3.4 ± 2.9 y) compared
to other regions. Therefore, all further analyses were done
with an adjustment for gender and therapy duration usimg
a generalised linear model.
Region-specific glycaemic control and diabetes therapy
At the start of diabetes treatment, fasting glucose was high-
er in the canton of Grisons (11.8 ± 4.4 mmol/l, p <0.001)
compared to the other regions. However, HbA1c levels did
not significantly differ between the regions (table 2). At the
time of the survey, fasting glucose and HbA1c were higher
(9.0 ± 2.5 mmol/l and 7.7 ± 1.6%, respectively, p <0.001)
in the Italian speaking part of Switzerland, whereas in pa-
tients from the German speaking part, both these paramet-
ers were lower (7.3 ± 2.0 mmol/l and 6.9 ± 1.0%, respect-
ively, p <0.001) than in the other regions (fig. 2, table 3).
The use of anti-hyperglycaemic drugs also differed
between regions. At the start of diabetes treatment, insulin
secretagogues (sulfonylureas and meglitinides) were more
often used in the Italian speaking part of Switzerland than
in other regions (57.5%, p <0.01). This difference was also
apparent at the time of survey (69.9%), when these sub-
stances were less often used in the French speaking part
(29.8%, p <0.01). In contrast, the use of biguanides (met-
formin) was highest in the French speaking part of Switzer-
land (86.1%), and lowest in the German speaking part
(74.8%, p <0.01). The use of thiazolidinedions was high-
er in the canton of Grisons compared to the other regions
(34.1%, p <0.01). Insulin was used significantly more often
in the German speaking part of Switzerland (27.0%) and
less often in the Italian speaking part (8.2%, p <0.01) (fig.
3, table 3).
Region-specific differences of other metabolic and
cardiovascular risk factors
There was no significant difference in total cholesterol,
HDL cholesterol or LDL cholesterol between the cultural
regions at the start of anti-diabetic treatment and at the time
of survey. In contrast, triglyceride levels were lower in the
French speaking part of Switzerland at both time points
(2.16 ± 1.28 mmol/l, 1.90 ± 1.08 mmol/l) and higher in the
canton of Grisons at the time of survey (2.81 ± 1.86 mmol/
l, p <0.01). These were differences that persisted when ad-
justed for insulin treatment.
Small differences in serum creatinine and blood pressure
were present at the start of anti-diabetic therapy between
the different regions, but did not last until the time of sur-
vey.
Patients in the German speaking part of Switzerland were
somewhat leaner at the beginning of anti-diabetic therapy
(BMI 29.7 ± 5.3 kg/m2), and patients in the French speak-
ing part had a higher BMI (31.2 ± 6.0 kg/m2), but these
were differences that did not persist during study enrol-
ment. A significant reduction in BMI was seen in both the
German and French speaking parts of Switzerland between
the time of therapy initiation and the time of the survey
(–0.3 and –0.9 kg/m2, respectively, p <0.001). Region spe-
cific changes in BMI as well as in parameters of glucose
and lipid metabolism are shown in figure 4.
Glycaemic control and BMI among other subgroups
There was no direct correlation between the change in
glycaemic control (HbA1c) and change in BMI between
initiation of therapy and current survey.
However, insulin therapy at the current survey was asso-
ciated with a significantly larger improvement of HbA1c
(–1.66 ± 2.33% with insulin, and –1.15 ± 1.91% without
insulin therapy; p = 0.001), compared to the start of anti-
diabetic therapy. Similarly, when comparing only patients
newly treated with insulin at the time of the current survey
(without insulin at the start of diabetes therapy) with those
never receiving insulin, there was a significant difference
in HbA1c improvement (–1.57 ± 2.30% vs. –1.13 ± 1.85%;
p = 0.03). At the same time, BMI decreased by 0.63 ± 2.60
kg/m2 without insulin, and increased by 0.36 ± 2.92 kg/m2
with insulin therapy (p <0.001).
Discussion
This cross-sectional and retrospective study shows that
glycaemic control and the type of anti-hyperglycaemic
therapy in patients with type 2 diabetes mellitus in general
Table 1: Demographic characteristics.
Patient characteristic Whole patient population German speaking region French speaking region Italian speaking region Grisons
Whole population of the region (2008),
n (%)
7701856 (100) 5500323 (71.4) 1678338 (21.8) 332736 (4.3) 190459 (2.5)
Number of patients, n (%) 1121 (100) 731 (65.2) 272 (24.3) 73 (6.5) 45 (4.0)
Number of physicians, n (%) 134 (100) 86 (64.2) 37 (27.6) 7 (5.2) 4 (3.0)
Patients per physician (no ± SD) 8.4 ± 4.3 8.5 ± 4.8 7.3 ± 2.9 10.4 ± 2.4 11.3 ± 3.9
Age (at start of therapy) (yrs ± SD) 60.5 ± 11.7 60.9 ± 11.2 59.7 ± 12.8 60.5 ± 12.2 59.8 ± 12.3
Duration of diabetes treatment (yrs ± SD) 5.5 ± 5.1 5.9 ± 5.3 * 4.7 ± 4.5 * 5.5 ± 5.1 3.4 ± 2.9 *
Male gender (%) 55.8 (52.9–58.7) 54.6 (51.0–58.2) 55.5 (49.6–61.4) 69.9 (59.4–80.4) * 55.6 (41.1–70.1)
Basic characteristics of treating physicians and patients belonging to the four cultural regions of Switzerland Mean ± SD or % (95% CI) (* parameter differs from other
regions p <0.01).
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practice in Switzerland are associated with the cultural re-
gion of the patient’s and physician’s place of residence.
With regard to regional group allocation, our patient
sample was representative for Switzerland. The anthropo-
metric and metabolic parameters of the cohort are com-
parable with other studies describing patients with type 2
diabetes mellitus and similar characteristics in Switzerland
and other European countries [8, 14, 15].
When comparing HbA1c levels of patients from the dif-
ferent regions, there was no difference at the time when
anti-hyperglycaemic treatment was initiated. Fasting gluc-
ose was, however, higher in the canton of Grisons. One
could speculate that people from this more rural and moun-
tainous region tend to visit their doctor less frequently, res-
ulting in a delay of diagnosis or treatment initiation. At
the time of study enrolment, however, fasting glucose had
reached a similar level as in the rest of the country. While
HbA1c-levels and fasting glucose were significantly lower
in the German speaking part compared to the other parts of
Switzerland at the time of survey, they were the highest in
the Italian speaking part. The HbA1c-levels in the French
speaking part of Switzerland did not differ from the other
regions, and interestingly, they were also similar to the
HbA1c levels observed in general practice in a European
study (7.21% vs. 7.2%) [8].
To look for possible reasons for these differences, we also
assessed the use of anti-diabetic therapy. In the Italian
speaking part, insulin secretagogues were used more often
at the most recent consultation compared to the other re-
gions, and insulin itself was used less frequent. On the oth-
er hand, the use of insulin in the German speaking part was
more common than in the rest of Switzerland. The non-
randomised and cross-sectional study design does not al-
low direct conclusions to be drawn concerning the effect
of choice of therapy on blood glucose control. When we
compared the change in HbA1c in all patients, however,
Table 2: Retrospective survey.
Parameter Whole collective German s. French s. Italian s. Grisons N
Metabolic parameters
Fasting glucose (mmol/l) 9.97 ± 3.86 9.81 ± 3.82 9.78 ± 3.85 10.81 ± 3.46 11.83 ± 4.43 ** 959
HbA1c (%) 8.28 ± 2.01 8.20 ± 1.93 8.27 ± 2.13 8.51 ± 2.01 8.97 ± 2.30 904
Creatinine (µmol/l) 82.2 ± 23.4 80.4 ± 22.0 * 84.9 ± 23.3 85.4 ± 20.5 85.3 ± 39.2 893
Total cholesterol (mmol/l) 5.75 ± 1.27 5.77 ± 1.31 5.71 ± 1.18 5.67 ± 1.33 5.81 ± 1.12 941
HDL cholesterol (mmol/l) 1.20 ± 0.40 1.19 ± 0.41 1.26 ± 0.40 1.16 ± 0.32 1.10 ± 0.30 801
LDL cholesterol (mmol/l) 3.40 ± 1.13 3.37 ± 1.11 3.46 ± 1.19 3.45 ± 1.12 3.39 ± 0.91 793
Triglycerides (mmol/l) 2.46 ± 1.69 2.54 ± 1.83 2.16 ± 1.28 * 2.59 ± 1.42 3.22 ± 1.88 850
Blood pressure and BMI
Systolic blood pressure (mm Hg) 144.1 ± 17.9 143.9 ± 18.3 146.4 ± 18.0 * 140.9 ± 14.5 139.4 ± 13.7 1051
Diastolic blood pressure (mm Hg) 86.5 ± 10.2 86.7 ± 10.4 86.5 ± 10.2 86.7 ± 9.1 82.2 ± 6.1 * 1052
Body mass index (kg/m2) 30.2 ± 5.5 29.7 ± 5.3 ** 31.2 ± 6.0 ** 30.1 ± 5.6 31.1 ± 4.7 1057
Diabetes treatment
Biguanides (%) 72.1 (69.4–74.8) 71.1 (67.7–74.5) 75.7 (70.5–80.9) 68.5 (57.8–79.2) 72.1 (58.7–85.5) 1077
Insulin secretagogues, total (%) 38.7 (35.7–41.7) 40.1 (36.4–43.8) 31.0 (25.2–36.8) 57.5 (46.2–68.8) * 27.9 (14.5–41.3) 1033
Thiazolidinediones (%) 5.3 (3.9–6.7) 5.1 (3.4–6.8) 5.4 (2.6–8.2) 4.2 (0–8.8) 9.3 (0.6–18.0) 1018
Insulin (%) 5.7 (4.3–7.1) 4.9 (3.3–6.5) 8.7 (5.3–12.1) 2.8 (0–6.6) 4.7 (0–11.0) 1069
Other (%) 2.7 (1.7–3.7) 2.7 (1.5–3.9) 3.9 (1.4–6.4) 0 0 1007
Metabolic parameters blood pressure and BMI (Mean ± SD) as well as diabetes related medication (% 95% CI) of the patients at the start of anti-diabetic treatment
(retrospective survey). N indicates the number of patients with this parameter available. (parameter differs from other regions * p <0.01, ** p <0.001).
Table 3: Current survey.
Parameter Whole collective German s. French s. Italian s. Grisons N
Metabolic parameters
Fasting glucose (mmol/l) 7.52 ± 2.23 7.25 ± 2.02 ** 7.79 ± 2.40 9.03 ± 2.49 ** 7.83 ± 2.77 1064
HbA1c DCCT (%) 7.03 ± 1.24 6.89 ± 1.02 ** 7.21 ± 1.58 7.72 ± 1.60 ** 7.18 ± 1.12 1071
Creatinine (µmol/l) 86.4 ± 27.5 86.6 ± 28.1 87.2 ± 26.5 83.5 ± 20.3 83.1 ± 33.1 999
Total cholesterol (mmol/l) 4.97 ± 1.09 4.96 ± 1.12 4.97 ± 1.05 4.99 ± 1.11 5.02 ± 0.95 1040
HDL cholesterol (mmol/l) 1.27 ± 0.43 1.29 ± 0.47 1.28 ± 0.34 1.11 ± 0.29 1.13 ± 0.29 951
LDL cholesterol (mmol/l) 2.80 ± 1.00 2.75 ± 0.99 2.94 ± 1.06 2.87 ± 0.97 2.54 ± 0.83 953
Triglycerides (mmol/l) 2.07 ± 1.18 2.09 ± 1.16 1.90 ± 1.08 * 2.27 ± 1.21 2.81 ± 1.86 * 978
Blood pressure and BMI
Systolic blood pressure (mm Hg) 138.5 ± 16.6 138.2 ± 16.4 139.7 ± 17.4 137.1 ± 17.4 140.0 ± 12.7 1118
Diastolic blood pressure (mm Hg) 81.4 ± 10.3 81.1 ± 10.4 82.1 ± 10.5 82.7 ± 9.3 79.3 ± 9.8 1114
Body mass index (kg/m2) 29.8 ± 5.6 29.5 ± 5.4 30.4 ± 6.2 29.9 ± 5.3 31.2 ± 4.5 1114
Diabetes treatment
Biguanides (%) 78.2 (75.8–80.6) 74.8 (71.6–78.0) * 86.1 (81.9–90.3) * 83.3 (74.7–91.9) 77.3 (64.9–89.7) 1097
Insulin secretagogues, total (%) 39.9 (37.0–42.8) 41.2 (37.6–44.8) 29.8 (24.4–35.2) * 69.9 (59.4–80.4) * 31.1 (17.6–44.6) 1063
Thiazolidinediones (%) 18.5 (16.1–20.9) 18.8 (15.9–21.7) 17.7 (12.9–22.5) 8.2 (1.9–14.5) 34.1 (20.1–48.1) * 1035
Insulin (%) 23.6 (21.1–26.1) 27.0 (23.8–30.2) * 17.1 (12.6–21.6) 8.2 (1.9–14.5) * 31.1 (17.6–44.6) 1112
Other (%) 9.6 (7.8–11.4) 7.6 (5.6–9.6) 18.7 (13.7–23.7) 2.9 (0–6.8) 7.9 (0–16.2) 1012
Metabolic parameters blood pressure and BMI (Mean ± SD) as well as diabetes related medication (% 95% CI) of the patients at the time of the survey (cross sectional
study). N indicates the number of patients with this parameter available. (parameter differs from other regions * p <0.01, ** p <0.001).
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the improvement was larger in those receiving insulin. It
is therefore likely that these factors are not independent.
In particular, the association of a lower rate of insulin use
with worse glycaemic control leads to the assumption that,
in some regions, cultural barriers towards a more intens-
ive and invasive therapy delay the escalation of therapy
from the easier, more applicable insulin secretagogues to
insulin. This assumption is supported by our finding that
other factors such as blood pressure, kidney function or ser-
um lipids did not show similar striking regional differen-
ces, which blood glucose control did. The only one of these
parameters that showed a slight difference between regions
at the time of the survey was serum triglycerides (lower
in the French speaking part of Switzerland, higher in the
canton of Grisons). A beneficial influence of the “Mediter-
ranean Diet” on this parameter in the French speaking re-
gion compared to the lack of such diet habits in the moun-
tainous region is a possible explanation for this finding
[16]. However, this would contrast with other results that
do not show an inter-regional difference in nutrition habits
[17].
Weight gain may also be one of the obstacles towards ap-
propriate glycaemic control. Overall, BMI was lower at the
time of the survey compared to the beginning of therapy.
However, patients with insulin treatment showed, along
with the advantage of better HbA1c, a gain in weight.
There are limitations to this study. As mentioned, the study
was neither conducted in a completely randomised nor in
a prospective way. Due to this design, the demographic
and anthropometric features of the study populations were
not completely equal. There was a higher proportion of
male patients in the Italian speaking part of Switzerland.
However, we did not find a difference in the change in
HbA1c or the use of anti-hyperglycaemic drugs between
the two genders between initiation of therapy and the cur-
rent survey. Nevertheless, all analyses were performed by
adjusting for gender and for duration of therapy. Another
limitation is a possible selection bias because only 134
(56%) of the 240 invited physicians finally participated in
the study. However, with the exception of the canton of
Grisons, there was no statistically significant difference in
the participation of physicians among the different regions.
Furthermore, due to the study design aiming at the accord-
ance of the patient distribution with the population distri-
bution between different regions, the power of the study
to detect differences in glycaemic control was not equal
among the regions. Finally, neither were outcome paramet-
ers measured at a central location / central laboratory nor
was it possible to assure certain standard conditions (e.g.,
fasting state for triglyceride measurements). Therefore, dif-
ferences due to various locations and conditions of out-
come measurements cannot be excluded.
In summary, this study shows that the cultural background
of patients and their physicians within a country might
be an important predictor of the use and outcome of hy-
perglycaemic medical therapy. Efforts to identify region-
specific cultural differences and the attempt to overcome
potential associated barriers should be emphasised in any
health care system when aiming for better patient care.
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